Maroun Ghossein, MD
Pulmonary Disease · Louisville, KYNPI 1619233723
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), education and food and beverage — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 65.5% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $15,475, more than ten times the $430 reported in 2019. Among pulmonary disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $314.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$22K
- Intuitive Surgical$9K
- Inari Medical, Inc.$592
- Stryker$296
- Amgen$281
- United Therapeutics Corporation$208
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$19,55358%
- Travel & lodging$4,30713%
- Food & beverage$4,74614%
- Education$5,38216%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $22,276 |
| Intuitive Surgical | 27 | $9,073 |
| Inari Medical, Inc. | 5 | $592 |
| Stryker | 3 | $296 |
| Amgen | 6 | $281 |
| United Therapeutics Corporation | 2 | $208 |
| Actelion Pharmaceuticals US, Inc. | 5 | $193 |
| Boehringer Ingelheim | 6 | $172 |
| Insmed, Inc. | 1 | $137 |
| Merck | 3 | $131 |
| Bayer | 1 | $125 |
| Sanofi | 1 | $120 |
| Sanofi-aventis U.S. LLC | 1 | $98 |
| La Jolla Pharmaceutical Company | 1 | $72 |
| Mylan Specialty L.p. | 3 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| GSK | 2 | $25 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $21 |
| Circassia Inc. | 1 | $19 |
| Ambu Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$21,840
- Da Vinci Surgical System$8,564
- FLOWTRIEVER CATHETER, S$983
- CT THROMBECTOMY SYSTEM KIT$295
- DUPIXENT$240
- FlowTriever$149
- Arikayce$137
- Adempas$125
- UPTRAVI$109
- OPSUMIT$109
- TAGRISSO$108
- BREZTRI$102
How this compares
$34,002 in reported general payments places this provider in the 90th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 66 | $902,736 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 274 | $295,392 |
| Dupixent PenDupilumab | 37 | $154,472 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $66,925 |
| TezspireTezepelumab-Ekko | 12 | $52,902 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $52,780 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $39,165 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $37,486 |
| SymbicortBudesonide/Formoterol Fumarate | 66 | $22,948 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $15,729 |
| Spiriva RespimatTiotropium Bromide | 16 | $9,288 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $9,152 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 303 | $8,536 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $7,778 |
| DuleraMometasone/Formoterol | 16 | $6,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $172 | $949,510131 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $25 | $387,337422 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $22,276 | $142,774151 claims |
| MerckDulera | $131 | $6,00616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
- Mohamed SaadLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.